This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): inhaled nitric oxide, INOflo (Japan), INOT27, IK-3001, INOtherapy
Description: INOmax (nitric oxide gas) is a drug administered by inhalation. Nitric oxide, the active substance in INOmax, is a pulmonary vasodilator.
Nitric oxide is a compound produced by many cells of the body. It relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3’,5’-monophosphate, which then leads to vasodilation.
INOmax is delivered with the INOmax DS device.
In December 2013, Ikaria announced that its investor group and employee shareholders have reached a definitive agreement to sell the Commercial Business to Madison Dearborn Partners in a transaction valued at approximately $1.6 billion.
Ikarias selling investor group comprises New Mountain Capital, Arch Venture Partners, Venrock, and 5AM Ventures, who created the company in 2007 in an approximately $670 million cash and stock merger of INO Therapeutics and Ikaria, Inc. New Mountain Capital was the lead investor, investing $220 million for a convertible preferred security with majority control. The seller of INO Therapeutics, The Linde Group retained a 17% equity position in the combined entity and is an additional member of the existing shareholder group.
The Ikaria shareholders will reinvest a portion of their proceeds into a 45% interest in the new parent Company.
The transaction also includes the separation of certain non-commercial products in the Ikaria...See full deal structure in Biomedtracker
Partners: Lee's Pharmaceutical Holdings Limited
Pink Sheet INOmax FDA Reviewers
Pink Sheet INOmax Clinical Development
Pink Sheet INOmax Clinical Protocols
Additional information available to subscribers only: